B/F/TAF (Low Dose)

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

HIV-1 InfectionHIV-1-infection

Phase 2

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Active, not recruitingNCT02881320

Gilead SciencesHIV-1 Infection

Start: 2016-09-21End: 2027-06-01Updated: 2026-09-24

Phase 4

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

RecruitingNCT06337032

Gilead SciencesHIV-1-infection

Start: 2024-08-27End: 2034-03-01Target: 350Updated: 2026-10-19

Related Papers

Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.

2024-04-127 citations

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.

2021-07-2214 citations